Biogen Inc

26 cze 2026, 19:51 UTC

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

25 cze 2026, 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting a notable upward trajectory since Thursday's close amid mixed broader market results.

24 cze 2026, 20:04 UTC

Biogen Inc shares are higher today, supported by a broader rally in the Biotechnology sector and increased interest noted on social media.

23 cze 2026, 23:21 UTC

Biogen Inc shares are higher in after-market trading, reaching a session high. No specific news was identified to explain the unusual price movement.

22 cze 2026, 23:46 UTC

Biogen Inc. shares traded lower in after-market hours following modest fluctuations since Monday's close, with the price dipping after a brief session high.

18 cze 2026, 20:05 UTC

Biogen Inc. plans to acquire RayThera Inc. for up to $1 billion, but shares are declining amid broader Biotechnology sector weakness.

17 cze 2026, 23:06 UTC

Biogen Inc announced a definitive agreement to acquire RayThera Inc. for up to $1 billion, enhancing its immunology pipeline. Shares are trading higher after the news.

16 cze 2026, 19:46 UTC

Biogen Inc. shares are lower amid an investigation announcement linked to the Phase 2 CELIA study's failure and failed negotiations over Skyclarys.

12 cze 2026, 19:51 UTC

Biogen Inc. shares are higher today, breaking a recent trend. Broader market sentiment is shaped by inflation concerns and optimism about upcoming IPOs.

11 cze 2026, 19:51 UTC

Biogen Inc is advancing as the biotechnology sector gains. Earlier in the session, shares pulled back from a high but resumed their upward trajectory.

10 cze 2026, 19:36 UTC

Biogen Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 2 CELIA study results. Shares are trading lower amid ongoing scrutiny.

9 cze 2026, 23:16 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Tuesday's close. The asset remains above its 20-day moving average.

8 cze 2026, 20:06 UTC

Biogen Inc. shares are lower amid negative sentiment over its Phase 2 CELIA study results, despite a recent upgrade to a Buy rating.

5 cze 2026, 19:16 UTC

Biogen shares are gaining following FDA's Breakthrough Therapy Designation for salanersen in spinal muscular atrophy, despite pulling back from earlier session highs.

4 cze 2026, 22:06 UTC

Biogen Inc. received FDA Breakthrough Therapy Designation for salanersen, aimed at treating spinal muscular atrophy, with shares trading higher in after-market hours.

3 cze 2026, 20:03 UTC

Biogen Inc. announced fourteen abstracts accepted for presentation at upcoming nephrology congresses, contributing to higher trading shares amid positive market sentiment.

2 cze 2026, 20:06 UTC

Biogen Inc. shares declined during Tuesday's session, continuing a trend of lower closes, amid broader weakness in the biotechnology sector.

1 cze 2026, 19:26 UTC

Biogen shares are lower following positive Phase 3 trial results for dapirolizumab pegol, despite significant improvements in disease activity for lupus patients.

29 maj 2026, 19:26 UTC

Biogen Inc. shares are trading lower today, reversing a recent trend of higher daily closes since Thursday's close. No specific news was identified.

28 maj 2026, 20:06 UTC

Biogen Inc shares are lower, continuing a downward trend since Wednesday. No specific news was identified to explain today's movement.

27 maj 2026, 20:06 UTC

RBC Capital raised its price target on Biogen Inc to $227, supporting shares' overall gain during Wednesday's trading amid positive pipeline developments.

26 maj 2026, 19:56 UTC

Biogen Inc. shares are lower following concerns over the failure of its Parkinson's drug BIIB122 in a Phase 2b trial.

22 maj 2026, 19:37 UTC

Biogen shares are higher following the Phase 2b LUMA study results for BIIB122, which showed over 90% kinase inhibition despite not meeting primary endpoints.

21 maj 2026, 23:02 UTC

Biogen Inc. shares declined in after-market hours following the failure of its Parkinson's treatment, BIIB122, to meet key trial endpoints in the Phase 2b LUMA study.

20 maj 2026, 23:51 UTC

Biogen Inc. shares are trading lower in after-market hours, reflecting broader market declines amid weak sentiment and macroeconomic factors affecting various sectors.

19 maj 2026, 23:36 UTC

Biogen Inc shares are trading higher in after-market hours, showing a modest recovery from earlier losses amid broader market caution over inflationary pressures.

18 maj 2026, 19:15 UTC

Biogen shares are lower amid negative sentiment from its CELIA trial results, which failed to meet primary endpoints, and ongoing investigations into potential securities violations.

15 maj 2026, 19:56 UTC

Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals, enhancing its drug portfolio. Shares are trading higher amid positive analyst ratings and target price increases.

14 maj 2026, 23:01 UTC

Biogen shares rose in after-market hours following positive topline results from the Phase 2 CELIA study on diranersen for early Alzheimer's disease.